KBC Group
AMLX icon

KBC Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

KBC Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$112K Buy
3,835
+1,972
+106% +$52.3K ﹤0.01% 1310
2026
Q2 		$33K Hold
1,863
– – ﹤0.01% 1811
2026
Q1 		$26K Buy
+1,863
New +$26.2K ﹤0.01% 1817

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

KBC Group's AMLX Position: Q3 2026 in Review

KBC Group increased its Amylyx Pharmaceuticals (AMLX) stake by 106% in Q3 2026, buying an estimated $52.3K and bringing the position to 3,835 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

KBC Group first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • KBC Group held 3,835 shares of Amylyx Pharmaceuticals worth $112K as of Q3 2026.
  • KBC Group bought 1,972 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $52.3K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1310 holding.
  • KBC Group first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.